Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139752

Published: 2020

Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-139668

Published: 2020

Journal Articles

Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease

Susanna A Curtis, MD, Raisa Balbuena-Merle, MD, Lesley Devine, PhD, Daniel Zelterman, John D. Roberts, MD, Jennifer Dearborn-Tomazos, MD MPH, Lauren Sansing, MD MS, Jeanne E. Hendrickson, MD

Blood (2018) 132 (Supplement 1): 1093.

https://doi.org/10.1182/blood-2018-99-117504

Published: 2018

Journal Articles

Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users

Susanna A Curtis, MD, Michelle Deveaux, Daniel Zelterman, Lesley Devine, PhD, Amanda M Brandow, DO, MS, John D. Roberts, MD

Blood (2017) 130 (Supplement 1): 3559.

https://doi.org/10.1182/blood.V130.Suppl_1.3559.3559

Published: 2017

Journal Articles

Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease

Susanna A Curtis, MD, Michelle Deveaux, Daniel Zelterman, Lesley Devine, PhD, Jeanne E. Hendrickson, MD, John D. Roberts, MD, Amanda M Brandow, DO, MS

Blood (2017) 130 (Supplement 1): 3414.

https://doi.org/10.1182/blood.V130.Suppl_1.3414.3414

Published: 2017

Journal Articles

The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Blood (2016) 128 (22): 1063.

https://doi.org/10.1182/blood.V128.22.1063.1063

Published: 2016

Journal Articles

Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial

Andrew R Branagan, MD, Eamon Duffy, Terri L Parker, MD, Stuart Seropian, MD, Connor Foster, Lin Zhang, Rakesh Verma, PhD(MDcal Oncology), MBA, MS, BCA, BS, Daniel Zelterman, PhD, Geliang Gan, PhD, Debra S. Brandt, DO, Jeremy Kortmansky, David H Witt, MD, Thomas M Ferencz, RPh, Madhav V Dhodapkar, MD

Blood (2016) 128 (22): 2139.

https://doi.org/10.1182/blood.V128.22.2139.2139

Published: 2016

NARROW

Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease

Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users

Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease

The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease

Daily Users of Marijuana with Sickle Cell Disease Report More Severe Pain Crisis Yet Have Similar Rates of Admission to Non-Users

Chronic Red Blood Cell Exchange Transfusion Therapy Does Not Impact Hospital Utilization or Ascq-Me Pain Domains in Adults Living with Sickle Cell Disease

The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only